billHR8471•Event Thursday, April 23, 2026Analyzed

PRIMATE Act

Bearish

Summary

The PRIMATE Act (HR8471) would prohibit importation of nonhuman primates except for AZA-accredited zoos, effectively banning their use in biomedical research. This early-stage bill, if enacted, would be a structural headwind for contract research organizations (CROs) that rely on imported primates, particularly Charles River Laboratories ($CRL) and Inotiv ($NOTV).

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.The PRIMATE Act would ban import of nonhuman primates for research, increasing costs for CROs.
  • 2.Charles River Laboratories ($CRL) and Inotiv ($NOTV) are directly exposed to this supply-side restriction.
  • 3.Bill is in early stage; monitor committee action for progression and potential market impact.

Market Implications

Current market impact is negligible as the bill is in early committee stage. However, $CRL and could face selling pressure if the bill gains legislative momentum. No real market data was provided, so no price references are included. Structural positioning: $CRL and are the most exposed, while alternative testing companies (e.g., organ-on-chip firms, mostly private) could benefit, but no public pure-play exists.

Full Analysis

The PRIMATE Act (Preventing Risky Importation of Monkeys to Avoid Toxic Exposures Act) was introduced on April 23, 2026, by Rep. Steube (R-FL) and referred to the House Committee on Ways and Means. The bill amends the Tariff Act of 1930 to prohibit the importation of nonhuman primates into the United States, with a narrow exception for AZA-accredited facilities that certify the primates will not be used in experiments or testing. There is no funding authorization or appropriation in this bill; it is a regulatory prohibition enforced by U.S. Customs and Border Protection, with civil penalties up to $50,000 per violation. No related signals or procurement data were provided, so no convergence analysis is possible. The bill's primary market impact is on the biomedical research sector, specifically contract research organizations (CROs) that import nonhuman primates for drug development and toxicity testing. Charles River Laboratories ($CRL) and Inotiv are the two largest publicly traded CROs with significant primate importation and breeding operations. If enacted, the bill would create supply constraints, increase costs, and potentially delay research projects, reducing revenue for these companies. The bill is in the earliest legislative stage; it has 7 cosponsors from both parties, indicating some bipartisan support, but it must clear the Ways and Means Committee, pass the House, and then the Senate. Legislative progress is likely slow, and the bill's ultimate passage is uncertain.

Intelligence Surface

Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures

Unconfirmed

No confirming evidence found yet from contracts, insider trades, or congressional activity

$$CRL▼ Bearish
①

What the bill does

Prohibition on importation of nonhuman primates except for AZA-accredited facilities that cannot transfer to testing or experiments, effectively banning import for biomedical research.

②

Who must act

US biomedical research organizations that import nonhuman primates for testing and experiments.

③

What happens

Reduced supply and increased cost of nonhuman primates, forcing researchers to seek alternative models or delay projects, raising operational costs for CROs.

④

Stock impact

Charles River Laboratories' Research Models and Services segment, which includes importation and breeding of nonhuman primates for research, faces supply constraints and higher costs, potentially reducing revenue and margin from this segment.

Key Legislators

Rep. Steube, W. Gregory [R-FL-17]

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderOct 19, 2026

Advancing Women's Health to Improve Outcomes in All Phases of Life

This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.

Exec OrderSep 18, 2026

Enhancing Program Integrity and Integrity and Interagency Coordination in the Administration of the H-1B Nonimmigrant Visa Program

This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.

Exec OrderSep 16, 2026

Providing Meaningful Water Quality Improvements Through Collaboration and Oversight of Federal Support

This executive order revokes Executive Order 13508, which had mandated Chesapeake Bay restoration efforts, and directs federal agencies to prioritize funding for direct, on-the-ground water quality projects. It also instructs the EPA to work with states to assess and encourage the repeal of stormwater management fees (rain taxes) that have burdened residents, aiming to reduce costs while maintaining environmental progress.

Free — no credit card

Get the next market-moving signal before the news does

HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.

Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.

Free forever plan · No credit card · Unsubscribe in one click

Want the live terminal too? Create a free account →